NasdaqGS:INVAPharmaceuticals
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA?
In August 2026, Innoviva, Inc. reported second-quarter revenue of US$119.59 million, up from US$100.28 million a year earlier, but swung from net income of US$63.69 million to a net loss of US$83.42 million, alongside a loss per share of US$1.14 from continuing operations.
Despite this quarterly loss, Innoviva’s six-month results showed revenue rising to US$217.59 million and net income increasing to US$103.18 million, while the company also completed a US$66.40 million buyback program that...